BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Trial Details

NCT ID
NCT06085742
Phase
PHASE2
Sponsor
University of Illinois Chicago
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Cyclophosphamide
  • Methotrexate
  • Capecitabine
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • I• Age ≥ 18 years of age at time of consent
  • ECOG performance status 0, 1, or 2
  • Histologically confirmed invasive breast cancer documented by biopsy or surgical excision.
  • Underwent potentially curative resection of primary breast tumor(s) with no gross residual local-regional disease (patients with microscopically po…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →